Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer
FEBS Letters · 2026-01 · 600 (2) · 215-225
DOI: 10.1002/1873-3468.70207 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, online erschienen am 28.10.2025. Verfasst von Diego Claro de Mello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo (USP), Brazil. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Enhancer of Zeste Homolog 2 Protein, Cell Dedifferentiation, Thyroid Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by dedifferentiation and radioiodine refractoriness. We investigated whether EZH2‐mediated H3K27me3 deposition represses thyroid differentiation genes (TDGs) in ATC cells. Online ChIP‐seq analyses and CUT&RUN confirmed EZH2/H3K27me3 enrichment at key TDGs ( SLC5A5 , NKX2‐1 , TSHR , FOXE1 , TPO ). Pharmacological inhibition of EZH2 with EPZ6438 reactivated TDG expression in RAS and BRAF‐mutated ATC cell lines and partially restored iodide uptake. Co‐treatment with the MEK1/2 inhibitor U0126 further enhanced TDG expression, consistent with MAPK‐dependent regulation of EZH2. These findings reveal EZH2 as a mediator of ATC dedifferentiation and highlight its inhibition as a potential strategy to restore thyroid function and sensitize tumors to radioiodine. Impact statement This study reveals how EZH2‐driven epigenetic remodeling controls thyroid cell dedifferentiation and loss of iodide uptake in anaplastic thyroid cancer. Our findings provide new mechanistic insights and highlight an FDA‐approved drug with repurposing potential, advancing both anaplastic thyroid cancer biology research and therapeutic perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo (USP), Brazil.
- Department of Medicine, Laboratory of Molecular and Translational Endocrinology Medicine, Federal University of São Paulo (UNIFESP), Brazil.
- Department of Biological Sciences, Institute of Environmental, Chemical and Pharmaceutical Sciences (ICAQF), Federal University of São Paulo (UNIFESP), Diadema, Brazil.
ORCID-Profile: Diego Claro de Mello
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- SBEM (Brazilian Society of Endocrinology and Metabolism)
Zitieren
APA
de Mello, D. C., Cristovão, M. M., Henrique, G., Rodrigues, V. G., Serrano-Nascimento, C., Kimura, E. T., & Fuziwara, C. S. (2026). Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer. FEBS Letters, 600(2), 215-225. https://doi.org/10.1002/1873-3468.70207
Vancouver
de Mello DC, Cristovão MM, Henrique G, Rodrigues VG, Serrano-Nascimento C, Kimura ET, et al. Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer. FEBS Letters. 2026;600(2):215-225. doi:10.1002/1873-3468.70207
BibTeX
@article{deMello2026,
author = {de Mello, Diego Claro and Cristovão, Marcella Maringolo and Henrique, Guilherme and Rodrigues, Vinicius Gonçalves and Serrano-Nascimento, Caroline and Kimura, Edna Teruko and Fuziwara, Cesar Seigi},
title = {Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer},
journal = {FEBS Letters},
year = {2026},
volume = {600},
number = {2},
pages = {215--225},
doi = {10.1002/1873-3468.70207}
}
EUVIMED